✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
BRL-50481 is an investigational drug.
There have been 6 clinical trials for BRL-50481. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2000.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Leukemia. The leading clinical trial sponsors are GlaxoSmithKline, Directorate General of Health Services of Bangladesh, and International Centre for Diarrhoeal Disease Research, Bangladesh.
Recent Clinical Trials for BRL-50481
|Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms||Chang Gung Memorial Hospital||N/A|
|A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia||Celgene||Phase 1/Phase 2|
|A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia||Mundipharma Research GmbH & Co KG||Phase 1/Phase 2|